8-KOther Events

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Mar 21, 2025)

Filed March 21, 2025For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. has announced a significant regulatory milestone with the U.S. Food and Drug Administration's (FDA) approval of its supplemental new drug application for AMVUTTRA® (vutrisiran). This expanded indication allows AMVUTTRA® to treat the cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adult patients. The approval is specifically for its ability to reduce key cardiovascular outcomes, including mortality, hospitalizations, and urgent visits related to heart failure. This FDA approval represents a major expansion of AMVUTTRA®'s therapeutic reach into a serious and progressive condition where unmet medical needs exist. The drug's demonstrated efficacy in reducing cardiovascular morbidity and mortality in ATTR-CM patients is a crucial development for the company and the patient community. Investors should view this as a positive catalyst, potentially driving significant revenue growth and solidifying Alnylam's position in the rare genetic disease market, particularly in amyloidosis.

Key Highlights

  • 1FDA approves supplemental new drug application for AMVUTTRA® (vutrisiran).
  • 2New indication is for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.
  • 3AMVUTTRA® approval aims to reduce cardiovascular mortality in ATTR-CM patients.
  • 4The approval also targets a reduction in cardiovascular hospitalizations.
  • 5Urgent heart failure visits are another key outcome reduced by AMVUTTRA® for ATTR-CM.
  • 6This expands the therapeutic potential and market opportunity for Alnylam Pharmaceuticals.

Frequently Asked Questions

The supplemental new drug application approval allows AMVUTTRA® to be used for the treatment of cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adult patients.

AMVUTTRA® is approved to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits in adult patients with ATTR-CM.

This approval significantly expands the addressable market for AMVUTTRA®, potentially leading to increased revenue and strengthening Alnylam's market leadership in the treatment of rare genetic diseases, particularly amyloidosis.

ATTR-CM stands for transthyretin-mediated amyloidosis cardiomyopathy. It is a progressive and often fatal disease caused by the buildup of abnormal transthyretin protein deposits in the heart, leading to cardiomyopathy.